RENOVARO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.49 USD | +1.36% |
|
+4.93% | -53.00% |
| May. 24 | Renovaro, Amsterdam UMC Cancer Center Plan to Form Joint Venture for Cancer Immunotherapy | MT |
| May. 24 | Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy | CI |
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 34.41M |
|---|---|---|---|---|---|
| Net income 2022 | -113M | Net income 2023 | -39M | EV / Sales 2022 | - |
| Net cash position 2022 | 1.99M | Net Debt 2023 | 3.9M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.89
x | P/E ratio 2023 |
-0.8
x | Employees | 12 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 74.45% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +1.36% | ||
| 1 week | +4.93% | ||
| 1 month | -5.70% | ||
| 3 months | -42.25% | ||
| 6 months | -55.26% | ||
| Current year | -53.00% |
1 week
1.32
1.75
1 month
0.821.75
Current year
0.825.25
1 year
0.395.25
3 years
0.3913.78
5 years
0.3913.78
10 years
0.3913.78
| Managers | Title | Age | Since |
|---|---|---|---|
Mark Dybul
CEO | Chief Executive Officer | 60 | 18-01-22 |
Lester Russell
CTO | Chief Tech/Sci/R&D Officer | - | 23-08-20 |
Greg Duczynski
CTO | Chief Tech/Sci/R&D Officer | - | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Alton
BRD | Director/Board Member | 58 | 19-12-31 |
Avram Miller
BRD | Director/Board Member | - | 23-10-10 |
James Sapirstein
BRD | Director/Board Member | 63 | 18-03-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 17 M€ | +4.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 1.49 | +1.36% | 242,910 |
| 24-05-30 | 1.47 | -.--% | 380,274 |
| 24-05-29 | 1.47 | -.--% | 235,462 |
| 24-05-28 | 1.47 | +3.52% | 1,172,716 |
| 24-05-24 | 1.42 | +7.58% | 1,138,589 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.
| 1st Jan change | Capi. | |
|---|---|---|
| -53.00% | 220M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- RENB Stock
